We are live on ! Find out more
PAWC

P.A.W. Capital Portfolio holdings

AUM $131M
1-Year Est. Return 46.14%
This Fund
S&P 500
This Quarter Est. Return
+8.74%
1 Year Est. Return
+46.14%
3 Year Est. Return
+67.18%
5 Year Est. Return
+64.85%
10 Year Est. Return
+1,459.33%
AUM
$94.2M
AUM Growth
-$4.78M
Cap. Flow
-$11.6M
Cap. Flow %
-12.36%
Top 10 Hldgs %
40.89%
Holding
73
New
9
Increased
6
Reduced
17
Closed
7

Top Buys

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$1.36M
2
MGNI icon
Magnite
MGNI
+$1.06M
3
KRYS icon
Krystal Biotech
KRYS
+$503K
4
CUE icon
Cue Biopharma
CUE
+$482K
5
GAIA icon
Gaia
GAIA
+$359K

Top Sells

Rank Stock Value
1
SMLR
Semler Scientific
SMLR
+$1.69M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$1.13M
3
ATTU
Attunity Ltd
ATTU
+$1.02M
4
AKBA icon
Akebia Therapeutics
AKBA
+$998K
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$951K

Sector Composition

Rank Sector Weight
1 Technology 32.35%
2 Healthcare 15.54%
3 Communication Services 14.8%
4 Industrials 10.95%
5 Consumer Staples 10.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
26
DELISTED
ChemoCentryx, Inc.
CCXI
$1.14M 1.21%
90,000
+5,000
+6% +$60.2K
CLLS
27
Cellectis
CLLS
$277M
$1.13M 1.2%
40,000
– –
MGNI icon
28
Magnite
MGNI
$2.76B
$1.08M 1.15%
+300,000
New +$1.06M
NMFC icon
29
New Mountain Finance
NMFC
$651M
$1.08M 1.15%
80,000
-15,000
-16% -$208K
LKFT
30
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$1.01M 1.07%
+9,000
New +$951K
T icon
31
AT&T
T
$159B
$840K 0.89%
33,100
-26,480
-44% -$649K
RDS.A
32
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$818K 0.87%
12,000
– –
VZ icon
33
Verizon
VZ
$195B
$801K 0.85%
15,000
– –
JNJ icon
34
Johnson & Johnson
JNJ
$618B
$760K 0.81%
5,500
– –
ABT icon
35
Abbott
ABT
$183B
$734K 0.78%
10,000
– –
CUE icon
36
Cue Biopharma
CUE
$113M
$724K 0.77%
2,667
+1,667
+167% +$482K
MO icon
37
Altria Group
MO
$114B
$724K 0.77%
12,000
– –
MRK icon
38
Merck
MRK
$322B
$709K 0.75%
10,480
-1,048
-9% -$66.8K
PFE icon
39
Pfizer
PFE
$143B
$705K 0.75%
16,864
-2,108
-11% -$81.2K
KO icon
40
Coca-Cola
KO
$377B
$693K 0.74%
15,000
– –
BP icon
41
BP
BP
$116B
$692K 0.73%
15,710
+836
+6% +$35K
PEP icon
42
PepsiCo
PEP
$190B
$671K 0.71%
6,000
– –
PG icon
43
Procter & Gamble
PG
$336B
$666K 0.71%
8,000
– –
OHI icon
44
Omega Healthcare
OHI
$15.1B
$655K 0.7%
20,000
– –
PM icon
45
Philip Morris
PM
$297B
$652K 0.69%
8,000
– –
TTE icon
46
TotalEnergies
TTE
$195B
$644K 0.68%
10,000
– –
DD icon
47
DuPont de Nemours
DD
$18.5B
$643K 0.68%
3,949
– –
GSK icon
48
GSK
GSK
$104B
$643K 0.68%
12,800
– –
XOM icon
49
ExxonMobil
XOM
$644B
$638K 0.68%
7,500
– –
ABBV icon
50
AbbVie
ABBV
$443B
$615K 0.65%
6,500
– –
1
2
3

Similar funds

EIM
Emmett Investment Management New York $131M AUM 25.7% 1-Year Est. Return
CIP
Castlefield Investment Partners Manchester $131M AUM
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
LC
LTG Capital Newton, Massachusetts $131M AUM 19.7% 1-Year Est. Return
EWP
Evergreen Wealth Partners Kalispell, Montana $131M AUM
OIM
Oder Investment Management Woodland Hills, California $130M AUM 25.54% 1-Year Est. Return
EPI
Eddie Patel Inc Chicago, Illinois $130M AUM

P.A.W. Capital's Q3 2018 Portfolio in Review

As of Q3 2018, P.A.W. Capital held 73 positions worth $94.2M, down 4.8% from $99M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

P.A.W. Capital withdrew a net $11.6M in Q3 2018, closing 7 positions and reducing 17 holdings. Its most notable exit was Akebia Therapeutics, an estimated $998K position sold in full.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, P.A.W. Capital opened a new position in Palvella Therapeutics worth $1.4M.

  • P.A.W. Capital's largest Q3 2018 buy was Palvella Therapeutics: 3,125 shares worth $1.4M.
  • P.A.W. Capital added most to Cue Biopharma in Q3 2018, an estimated $482K increase.
  • P.A.W. Capital's biggest Q3 2018 reduction was Semler Scientific, cutting an estimated $1.69M.
  • P.A.W. Capital fully exited Akebia Therapeutics in Q3 2018, selling an estimated $998K.
  • P.A.W. Capital's ten largest holdings make up 41% of its $94.2M portfolio in Q3 2018.
  • P.A.W. Capital opened 9 new positions and closed 7 in Q3 2018.
  • P.A.W. Capital's portfolio value fell 4.8% quarter-over-quarter to $94.2M.

Based on P.A.W. Capital's 13F filing for Q3 2018, filed 24 Oct 2018.